UK Markets closed

Clinigen Group Plc (CLIN.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
925.00+1.00 (+0.11%)
At close: 05:15PM BST
Full screen
Previous close924.00
Open924.00
Bid0.00 x 0
Ask0.00 x 0
Day's range924.00 - 925.00
52-week range9.25 - 948.05
Volume1,786,937
Avg. volume1,679,225
Market cap1.234B
Beta (5Y monthly)1.47
PE ratio (TTM)41.48
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.08 (0.82%)
Ex-dividend date02 Dec 2021
1y target estN/A
  • Business Wire

    Form 8.3 - CLINIGEN GROUP PLC

    NEW YORK, March 29, 2022-- FORM 8.3

  • Business Wire

    Form 8.5 (EPT/NON-RI) - CLINIGEN GROUP PLC

    LONDON, March 08, 2022-- FORM 8.5 (EPT/NON-RI)

  • Business Wire

    Humanigen Launches Managed Access Program for Lenzilumab

    BURLINGAME, Calif. & DUBLIN & LONDON, February 10, 2022--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program ("LenzMAP™"). Clinigen Group plc ("Clinigen"), a global pharmaceutical Services and Products company, is implementing the program. Lenzilumab